Companies showcasing equipment and services at the event include Shilpa Biologicals (Booth 12J33), which is announcing the ...

Access Part 1 of this interview, in which Piervincenzi explains how benchmarking could reward reliable generic drug suppliers ...

Machine-readable digital standards integrated into LIMS, ELNs, and regulatory platforms reduce transcription risk, streamline ...

The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps. When Merck and Moderna's INTerpath-001 trial of ...

PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical ...

Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence. The FDA's September 22 direct final rule, which swaps ...

Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions ...

Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy. In part 2, of a 3-part interview, Ronald T. Piervincenzi, ...

Understand why the FDA's shift toward single pivotal Phase III trials requires establishing a drug's mechanistic hypothesis ...